infed stability after reconstitution

National Library of Medicine Changes in serum ferritin levels represent the changes in calculated cellular non-heme iron levels. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents. 0000012149 00000 n Administer daily doses of no more than 2 mL of Infed until the total required dose is administered. Bone scans involving 99m Tc-diphosphonate have been reported to show a dense, crescentic area of activity in the buttocks, following the contour of the iliac crest, 1 to 6 days after intramuscular injections of Infed. Package insert / product label If patient is standing, administer IM injection in buttock of the leg opposite the patients weight-bearing leg; if supine, place patient in a lateral position with the injection site uppermost. <> Administer test dose prior to first therapeutic dose. 0000001877 00000 n (See Boxed Warning.) Infed (iron dextran injection USP) containing 50 mg of elemental iron per mL, is available as a dark brown, slightly viscous, sterile solution in 2 mL single-dose amber vials in cartons of 10 (NDC 0023-6082-10). hO4,qv(8p]4SXs?_k^ '4["G!@` \ For all medical inquiries contact: Each mL of iron dextran injection is equivalent of 50 mg of elemental iron. Int J Pharm Compd. 0000005669 00000 n Cancer Chemother Pharmacol. The most common adverse reactions, including laboratory abnormalities, (20%) are leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase,. 0000026302 00000 n 0000035990 00000 n Administer test dose prior to administration of initial and subsequent therapeutic doses of the drug and observe patient closely. 8600 Rockville Pike . 0000030666 00000 n 0000011536 00000 n Hilleman DE, McEvoy GK, Bailey RT Jr, Reich J. Hosp Pharm. Risk Summary Epinephrine should be immediately available. Varicella (Var) Measles, Mumps, Rubella (MMR) Measles, Mumps, Rubella, % RRd::||7?_EeYU2&*[-%yWU0J@eZZ+)_P2B A_`T During all Infed administrations, observe for signs or symptoms of anaphylactic-type reactions. Bethesda, MD 20894, Web Policies National Library of Medicine !m This site complies with the HONcode standard for trust- worthy health information: verify here. endobj l Sm3G.E7=" r7/[^;q|= Isoproterenol or similar beta-agonist agents may be required in these patients. INFeD should not normally be given in the first four months of life. All adult and pediatric patients receiving Infed require periodic monitoring of hematologic and iron parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation). After reconstitution with 19 ml water for injections, the product contains 10 mg/ml voriconazole and 160 mg/ml SBECD. If there is no reaction after 1 hour continue. trailer << /Size 254 /Info 216 0 R /Root 219 0 R /Prev 331519 /ID[<618a70ff49b482af49be42cc5de1ac5d><4f4e9802b6496a1513efa6cfdffb7212>] >> startxref 0 %%EOF 219 0 obj << /Type /Catalog /Pages 213 0 R /Metadata 217 0 R /PageLabels 211 0 R >> endobj 252 0 obj << /S 769 /T 901 /L 982 /Filter /FlateDecode /Length 253 0 R >> stream Ling J, Gupta VD. Chemical and physical bases determining the instability and incompatibility of formulated injectable drugs. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). . Dilution not recommended by manufacturers, but there have been reports of the total calculated dose of iron dextran being diluted in 2501000 mL of 0.9% sodium chloride injection for IV infusion [off-label]. 12.1 Mechanism of Action Nervous system disorders: Convulsions, seizures, syncope, headache, unresponsiveness, paresthesia, dizziness, numbness, unconsciousness, altered taste. . Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. xref 2 0 obj government site. 0000002803 00000 n [qsXBp^z\}L88l$ 6 v~\^bdQl=;GmC;c}_6u6bMUb#&YlKS;ii.HGaToD7Wg%.[vIo6y/tIiVool#8is?8dK Patheon Italia S.p.A. 0000039715 00000 n Therefore, administration of subsequent test doses during therapy should be considered. 2025C; excursions permitted to 1530C. 8600 Rockville Pike The product should be further diluted in a suitable diluent prior to infusion. 0000037333 00000 n For solution and drug compatibility information, see Compatibility under Stability. Administer the test dose at a gradual rate over at least 30 seconds into the buttock. PMC Animal Data 5.2 Delayed Reactions 5.4 Iron Overload Please check for further notifications by email. Note: The table and accompanying formula are applicable for dosage determinations only in patients with iron deficiency anemia; they are not to be used for dosage determinations in patients requiring iron replacement for blood loss. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. 0000008494 00000 n ), Epinephrine should be immediately available in the event of acute hypersensitivity reactions. Administer a test Infed dose prior to the first therapeutic dose. 1 INDICATIONS AND USAGE INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response . 4. 0000001797 00000 n Blood volume . Anaphylaxis and other hypersensitivity reactions have been reported after uneventful test doses as well as therapeutic doses of iron dextran injection. Trace amounts of unmetabolized iron dextran are present in human milk. @['/=yWb7m$Hl%B0p`5s['9t YR=7lVnsuQ~ Patients with a history of significant allergies and/or asthma may have an increased risk of hypersensitivity reactions [see Dosage and Administration (5.1)]. It should be understood that these half-life values do not represent clearance of iron from the body. If the patient is standing, he/she should be bearing his/her weight on the leg opposite the injection site, or if in bed, he/she should be in the lateral position with injection site uppermost. official website and that any information you provide is encrypted H|TMs6Wu*Q6i\l.` The formula shown below is based on the approximation that 1 mL of normocytic, normochromic red cells contains 1 mg of elemental iron: Replacement iron (in mg) = Blood loss (in mL) x hematocrit, Example: Blood loss of 500 mL with 20% hematocrit. The site is secure. Initial U.S. Approval: 1974 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 0000013099 00000 n CAS number: 9004-66-4. . *Qp"Q!J For information on systemic interactions resulting from concomitant use, see Interactions. Infed should be injected only into the muscle mass of the upper outer quadrant of the buttock - never into the arm or other exposed areas - and should be injected deeply, with a 2-inch or 3-inch 19 or 20 gauge needle. Data Each mL contains the equivalent of 50 mg of elemental iron (as an iron dextran complex), approximately 0.9% sodium chloride, in water for injection. Therapy, thus, should aim at not only replenishment of hemoglobin iron but iron stores as well. Clinical Considerations The .gov means its official. Monitor for iron toxicity when Infed is used in patients with serious impairment of liver function. HdTr0+(R^ The 5 hour value was determined for 59Fe iron dextran from a study that used laboratory methods to separate the circulating 59Fe iron dextran from the transferrin bound 59Fe. Concomitant use of angiotensin-converting enzyme inhibitor drugs may increase the risk for anaphylactic-type reactions to an iron dextran product. The amount of vancomycin to treat an adult infection is superior to 1 g and so the volume administered can be higher than 100 mL. Solution Stability: VIDAZA reconstituted for intravenous administration may be stored at 25C (77F), but administration must be completed within 1 hour of reconstitution. INFeD (Iron Dextran Injection USP) containing 50 mg of elemental iron per mL, is available in 2 mL single dose amber vials (for intramuscular or intravenous use) in cartons of 10 (NDC 52544-931-02). . In patients with CKD receiving an ESA, administer sufficient iron to maintain selected targets of iron therapy (i.e., transferrin saturation and serum ferritin concentrations); periodically monitor these iron indices and use results (in conjunction with hemoglobin concentrations and ESA dosage) to guide iron therapy. Brand and Other Names: INFeD, Dexferrum Classes: Iron Products Dosing & Uses AdultPediatric Dosage Forms & Strengths injectable solution 50mg (Fe)/mL Iron-deficiency Anemia 25-100 mg IV or deep. Alternatively, the total dose may be calculated using the formulas below: Dose (mL) = 0.0442 (Desired Hb - Observed Hb) x LBW + (0.26 x LBW), Desired Hb = the target hemoglobin in g/dL [Normal hemoglobin (males and females) for body weight over 15 kg (33 lbs) is 14.8 g/dL. Please enable it to take advantage of the complete set of features! Do not administer Infed to patients with iron overload [see Warnings and Precautions (5.4)]. Based on the above factors, individuals with normal hemoglobin levels will have approximately 33 mg of blood iron per kilogram of body weight (15 mg/lb). INFeD (iron dextran injection), for intravenous or . HlTM6(R;!$+g}4h*I:-~`wIg;g5#I:X3Gs3dlg7E%~KyV0=^z@X,/%OE9oCz?=P%!XYUX8]hMW;2m%}?={ Pov5J%3LaA@a9"099^eiqk5r#ZH34`&`Eaj,@6kbBQ(BPt"`32n'OV4=:yOM2hf}"V@> 2.2 Recommended Dosage for Iron Deficiency Anemia INFeD should be used with caution in individuals with histories of significant allergies and/or asthma. Distributed into milk (as traces of unmetabolized iron dextran); use with caution in nursing women. . Known hypersensitivity to iron dextran or any ingredient in the formulation. Reports in the literature from countries outside the United States (in particular, New Zealand) have suggested that the use of intramuscular iron dextran in neonates has been associated with an increased incidence of gram-negative sepsis, primarily due to E. Coli. The need for chemical compatibility studies of subcutaneous medication combinations used in palliative care. In mice, rats, rabbits, and possibly hamsters, it has been demonstrated that these complexes may produce sarcoma following repeated administration of large or small doses of iron-carbohydrate complexes at a single injection site. INFeD is given undiluted at a slow gradual rate not to exceed 50 mg (1 mL) per minute. DOSAGE AND ADMINISTRATION 5 If reconstituted vaccine is not used immediately or comes in a multidose vial, be sure to clearly mark the vial with the date and time the vaccine was reconstituted, maintain the product at 2-8C (36-46F); do not freeze, and use only within the time indicated on chart above. The extent of risk for anaphylactic-type reactions following exposure to any specific iron dextran product is unknown and may vary among the products. trailer A subsidiary of Watson Pharmaceuticals, Inc. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic Infed dose. 0000037133 00000 n . Drug interactions involving Infed have not been studied. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during Infed administration. Bonnie E. Kirschenbaum, M.S., Clifton J. Latiolais, Sc.D., Stability of injectable medications after reconstitution, American Journal of Hospital Pharmacy, Volume 33, Issue 8, 1 August 1976, Pages 767791, https://doi.org/10.1093/ajhp/33.8.767. Stability of acyclovir sodium after reconstitution in 0.9% sodium chloride inje ction and storage in polypropylene syringes for pediatric use. A current package insert for the iron dextran product being used should always be reviewed, since these package inserts are periodically updated, and the product is currently made by more than one manufacturer. . Cardiac disorders: Cardiac arrest, tachycardia, bradycardia, arrhythmias. Iron dextran was stable in the four parenteral nutrient solutions after 18 hours of room-temperature storage. Infed is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. sharing sensitive information, make sure youre on a federal Fatal anaphylactic reactions are possible. (5.3). Distribution Data sources include IBM Watson Micromedex (updated 2 Apr 2023), Cerner Multum (updated 17 Apr 2023), ASHP (updated 10 Apr 2023) and others. . Corrections in compilation of information on stability of injectable medications after reconstitution. Hbd`ab`ddpwwvL)IMN5405NKIa!#6= v`b`fd4/9(3=DA!YAR1%? Sensitivity (e.g., anaphylactoid or anaphylactic) reactions; can be immediate or delayed and vary widely in severity. (See Boxed Warning.). .14.8 g/dl 7.1 Drug/Laboratory Test Interactions The Summary of Product Characteristics (SmPC) recommends reconstituting a 1 g vial with 20 mL of water for injection (WFI), then diluting it in 100 mL of saline solution. ferrous sulfate, Venofer, Aranesp, epoetin alfa, Injectafer. Watson Pharma, Inc. . Recommended formula (where Wt = patient's weight in kg and Hbo = observed hemoglobin in g/dL) for calculating total dosage of iron dextran injection (in mL): Use the following formula to calculate required total dosage of iron dextran injection (in mL): Infants weighing <5 kg (11 lbs): Maximum daily dosage is 25 mg of iron. Federal government websites often end in .gov or .mil. Excretion Copyright 2021 GlobalRPH - Web Development by, IV Dilutions Medication Reference and Infusion Guidelines, Renal dosing for healthcare professionals, HONcode standard for trust- worthy health, 7 Natural Remedies for Rheumatoid Arthritis, How Prenatal Counseling Can Help You Through Pregnancy. If no adverse reactions are observed, INFeD can be given according to the following schedule until the calculated total amount required has been reached. 0000002696 00000 n Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. endobj CONTRAINDICATIONS 0000004132 00000 n INFeD preparation: Administer by deep IM injection using a 2- or 3-inch, 19- or 20-gauge needle into the upper outer quadrant of the buttock only. The stability of injectable medications after reconstitution is presented. Large doses of iron dextran (5 mL or more) have been reported to give a brown color to serum from a blood sample drawn 4 hours after administration. Children weighing >15 kg (33 lbs): Use the following formula (where Wt = patient's weight in kg and Hbo = observed hemoglobin in g/dL): [0.0442 Wt (14.8 g/dL Hbo)]+ (0.26 Wt) = total dosage of iron dextran injection (mL). N}F( 9N(i{:%NISD;%NIS*T1 2.Intramuscular Injection - PRIOR TO RECEIVING THEIR FIRST INFeD THERAPEUTIC DOSE, ALL PATIENTS SHOULD BE GIVEN AN INTRAMUSCULAR TEST DOSE OF 0.5 mL. Fatal reactions have also occurred in situations where the test dose was tolerated. Importance of informing patients of other important precautionary information. Administer the test dose at a gradual rate over at least 30 seconds. PMC The https:// ensures that you are connecting to the The following adverse reactions associated with the use of Infed were identified in clinical studies or postmarketing reports. Oral iron should be discontinued prior to administration of INFeD. The onset is usually 24 to 48 hours after administration and symptoms generally subside within 3 to 4 days. 06\ zp#2j)kS \(nd+?5R . There have been several reports in the literature describing tumors at the injection site in humans who had previously received intramuscular injections of iron-carbohydrate complexes. ~q`C34&rAd oG Brand names: Dexferrum, INFeD Adverse reactions experienced following administration of Infed may exacerbate cardiovascular complications in patients with pre-existing cardiovascular disease. The total volume of Infed required for the treatment of iron replacement for blood loss is determined from an appropriate formula listed [see Dosage and Administration (2.3)]. 0000008022 00000 n 0000009066 00000 n . What are the possible side effects of INFeD? Discontinue oral iron therapy prior to initiation of iron dextran therapy. Crosses the placenta and small amounts of iron apparently reach the fetus. J Pediatr Pharmacol Ther. David McAuley, Pharm.D. MeSH Discontinue administration of any iron-containing products prior to administration of Infed. 8.4 Pediatric Use LBW = Lean body weight in kg [A patients lean body weight (or actual body weight if less than lean body weight) should be utilized when determining dosage.] 0000008617 00000 n Similar effects were observed in mice and rats on administration of a single dose of 125 mg iron/kg. Women's Bond NFT Collection Observe patients for at least one hour after the test dose before administering the remainder of the initial therapeutic dose. Parenteral iron dextran therapy: a review. official website and that any information you provide is encrypted Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant persons with intravenous iron administration (such as Infed) which may have serious consequences on the fetus such as fetal bradycardia, especially during the second and third trimester. The test dose should be administered in the same recommended test site and by the same technique as described in the last paragraph of this section. The table and formula described under I.Iron Deficiency Anemia are not applicable for simple iron replacement values. 88 0 obj<>stream 0000002072 00000 n 0000007595 00000 n Assess baseline hematologic (hemoglobin and hematocrit) and iron storage parameters (serum iron, total iron binding capacity, and percent saturation of transferrin) to monitor response to therapy. 0000009371 00000 n J Parenter Sci Technol. Excessive dosages of Infed may lead to accumulation of iron in storage sites potentially leading to hemosiderosis. Excess storage of iron and a syndrome similar to hemosiderosis possible when used for anemia not attributable to iron deficiency (e.g., those with hemoglobinopathies and other refractory anemias that might be erroneously diagnosed as iron deficiency anemias). 0000008737 00000 n A patients lean body weight (or actual body weight if less than lean body weight) should be utilized when determining dosage. Large intravenous doses, such as used with total dose infusions (TDI), have been associated with an increased incidence of adverse reactions. To avoid injection or leakage into the subcutaneous tissue, a Z-track technique (displacement of the skin laterally prior to injection) is recommended. 8.2 Lactation Administer undiluted by slow (50 mg/minute) IV injection; some preparations (i.e., INFeD) also are FDA-labeled for IM injection. 0000002019 00000 n If a hypersensitivity reaction occurs with the test dose, manage medically and do not administer further doses of Infed. Increased Risk of Toxicity in Patients with Underlying Conditions FOIA In doses 500 mg, iron dextran plasma concentrations decrease exponentially with a half-life of about 6 hours. Following administration of Infed, circulating iron dextran is split by the cells of the reticuloendothelial system into its components of iron and dextran. Administer test dose by intended route of administration for therapeutic doses prior to initial therapeutic dose. Each days dose should not exceed 0.5 mL (25 mg of iron) for infants with body weight under 5 kg (11 lbs); 1 mL (50 mg of iron) for children with body weight under 10 kg (22 lbs); and 2 mL (100 mg of iron) for other patients. INFeD belongs to a class of drugs called Iron Products. Intravenous admixtures - preparation and infusion guidelines This reference contains standard dilutions including IV admixture drug concentration, infusion volumes, and infusion rates. The etiology of these reactions is not known. . Stability of aminophylline injection in three parenteral nutrient solutions. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. tran [6]. Does not stimulate erythropoiesis nor does it correct hemoglobin disturbances not caused by iron deficiency. Iron Deficiency Anemia: Periodic hematologic determination (hemoglobin and hematocrit) is a simple and accurate technique for monitoring hematological response, and should be used as a guide in therapy. Do Not Copy, Distribute or otherwise Disseminate without express permission. Administer a test dose of Infed prior to the first therapeutic dose [see Dosage and Administration (2.4)]. May increase risk for anaphylaxis with concomitant use, Bone scans using imaging agents labeled with technetium Tc 99m (diphosphonate), Dense, crescentic areas of activity along the contour of the iliac crest, visualized 16 days after IM administration of iron dextran, Possible reduced bone uptake, marked renal activity, and excessive blood pool and soft tissue accumulation, Therapeutic duplication; increased risk for iron toxicity, Serum iron determinations (especially colorimetric assays) may not be meaningful for 3 weeks following the administration of iron dextran, Serum ferritin concentrations peak approximately 79 days following an IV iron dextran dose and slowly return to baseline over a period of about 3 weeks, Bone marrow examination for iron stores may not be meaningful for prolonged periods following iron dextran therapy because residual iron dextran may remain in the reticuloendothelial cells, May cause falsely elevated values of serum bilirubin and falsely decreased values of serum calcium, Prolonged partial thromboplastin time following IV administration of iron dextran when the blood sample for the test is mixed with anticoagulant citrate dextrose solution but not sodium citrate solution, Blood typing and cross-matching unaffected. . . 2010 Mar;54(2):95-103. doi: 10.4103/0019-5049.63637. The 20 hour value reflects a half-life determined by measuring total 59Fe, both circulating and bound. Infed is a registered trademark of Allergan Sales, LLC. During administration of any iron dextran dose, observe for manifestations of anaphylactic-type reactions. F'T9CQU!haSuYn5yd)}^O:Cu) ^>?9#f+R' 0000003686 00000 n W = body weight in kg 0000002986 00000 n 0000032198 00000 n Bookshelf Use of 5% dextrose injection instead of 0.9% sodium chloride injection may be associated with a higher incidence of local pain and phlebitis. Ferentino, Italy 03013, Distributed By: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported following the parenteral administration of iron dextran products, including Infed. The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies. 3. Use with caution in patients with a history of clinically important allergies and/or asthma. Disclaimer. 0000000016 00000 n Hb```f`` l,/`"`FOB/r7}UL 0000036781 00000 n 1986 Jul-Aug;40(4):142-63. 1984 Mar;19(3):202, 207, 211-3. HTP=0+21T !uC/OR@OwUl yakX2X#a;AFr=E!5#,Uyfl-D)@e !wGOCnGXO}>;WYQPdyJH{x4Wxm;Nys6;YH|J! Vhv Before Advise patients to immediately report any symptoms of hypersensitivity that develop during and following Infed administration such as arthralgia, backache, chills, dizziness, moderate to high fever, headache, malaise, myalgia, nausea, and vomiting [see Warnings and Precautions (5.1)]. Such reactions have been generally characterized by sudden onset of respiratory difficulty and/or cardiovascular collapse. <> Please enable it to take advantage of the complete set of features! Advise pregnant persons about the risk of hypersensitivity reactions which may have serious consequences for the fetus [see Use in Specific Populations (8.1)]. Systemic exposure to iron dextran may be increased. 0000046691 00000 n The development and health benefits of breastfeeding should be considered along with the mothers clinical need for Infed in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. The half-life of free iron in the plasma circulation is approximately 5 hours. Vancomycin hydrochloride is an antibiotic belonging to the glycopeptide family and acts by inhibiting the synthesis of the peptidoglycan wall. 0000009538 00000 n Careers. Iron Replacement for Blood Loss: Some individuals sustain blood losses on an intermittent or repetitive basis. 0000015331 00000 n 2. 0000003708 00000 n %PDF-1.3 % INFeD should be injected only into the muscle mass of the upper outer quadrant of the buttock - never into the arm or other exposed areas - and should be injected deeply, with a 2-inch or 3-inch 19 or 20 gauge needle. The intramuscular injection of iron-carbohydrate complexes may be associated with an increased risk of carcinogenesis. Sodium hydroxide and/or hydrochloric acid may have been used to adjust pH. Should be administered by qualified individuals with ready access to resuscitation equipment and appropriate agents for the treatment of a severe allergic or anaphylactic reaction (e.g., epinephrine, or isoproterenol in patients receiving -adrenergic blocking agents). After reticuloendothelial cells separate iron from the iron dextran complex, iron becomes a part of the bodys total iron stores. In iron-deficient patients, reticulocytosis may begin by the 4th day following an IV infusion of the total calculated dose of iron dextran and reaches a maximum by about the 10th day. Administer only in a setting where resuscitation equipment and medications are available. Anaphylaxis and other hypersensitivity reactions have been reported after uneventful test doses as well as therapeutic doses of iron dextran injection. Available data from postmarketing reports with iron dextran use in pregnancy are insufficient to assess the risk of major birth defects or miscarriage. The following information about each drug is given in tabular format: drug to be reconstituted and size of package; recommended route(s) of administration; recommended diluent, quantity to be used and resultant concentration; stability after initial dilution; and stability after further dilution; and stability of frozen antibiotics. 2009 Jan;14(1):48-56. doi: 10.5863/1551-6776-14.1.48. INFeD should be used with caution in individuals with histories of significant allergies and/or asthma. Sv DOSAGE FORMS AND STRENGTHS VIDAZA (azacitidine for injection) is supplied as lyophilized powder in 100 mg single-use vials. 0000047340 00000 n The half-life of total iron, including both circulating and bound, is approximately 20 hours. (See Special Populations under Pharmacokinetics.). THE TEST DOSE SHOULD BE ADMINISTERED AT A GRADUAL RATE OVER AT LEAST 30 SECONDS. It should not be used during the acute phase of infectious kidney disease. BILy@yK5] I(Y+ u YV ;bPqZ9~3oG RqK|"@k!/<9 .*JIr|R$ck4w8Szd*-qK"#AgFIyVsT`PtP_-tO=jq"~.^^2={nZU$ , 0000024030 00000 n CAREFULLY BEFORE ACCESSING OR USING THIS SITE. . The maximum daily dose of INFeD should not exceed 2 mL. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. . TVFRk-ijJ>r$QK{\[8 `v,heF-ZQ4R70rj !sGE Careers. Dose (mL) = 0.0442 (Desired Hb - Observed Hb) x W + (0.26 x W), Based on: Desired Hb = the target Hb in g/dl. ], Observed Hb = the patients current hemoglobin in g/dL. Allergan USA, Inc. Unauthorized use of these marks is strictly prohibited. HdTn0D Use only in patients in whom a clearly established indication for parenteral iron therapy exists, confirmed by appropriate clinical and laboratory tests. (See Anaphylaxis under Cautions.) Available for Android and iOS devices. The .gov means its official. Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. . 2007 Jan;12(1):53-9. doi: 10.5863/1551-6776-12.1.53. 5. Possible increased pathogenicity of certain microorganisms; not recommended for use during the acute phase of infectious renal disease. .65 mL/kg of body weight, b. Risk of developing potentially life-threatening anaphylactic reactions. Accessibility Unwarranted therapy with parenteral iron will cause excess storage of iron with the consequent possibility of exogenous hemosiderosis. If the patient is standing, he/she should be bearing his/her weight on the leg opposite the injection site, or if in bed, he/she should be in the lateral position with injection site uppermost. INDICATIONS AND USAGE: Injectafer is indicated for the treatment of iron deficiency anemia in adult patients: >who have intolerance to oral iron or have had unsatisfactory response to oral iron; equivalent to 50 mg of elemental iron per mL. Iron dextran was stable in the four parenteral nutrient solutions after 18 hours of room-temperature storage. 0000010877 00000 n (8(YP VPRX_RY_ 4483%3(3XLLM|?|w! . used within 6 hours after reconstitution.If RZV is stored after reconstitution, store at recommended storage conditions and reagitate prior to administration.
The Sandbank, West Mersea Menu, How Do I Stop My Balls From Being Sticky, Puppies For Sale In Oxnard, Nationwide Brokerage Solutions Carriers, Articles I